Form 4: Acrivon Therapeutics: Chief Legal Officer Tax Withholding

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported a disposition of 558 common shares for tax withholding purposes.

Summary

• Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on October 17, 2025.
• The transaction involved the disposition of 558 shares of Common Stock.
• These shares were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• The price per share for the disposition was $1.81.
• Following this transaction, Mary Miller beneficially owns 34,739 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding purposes, which is a neutral event for the company's operational or financial performance.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report specific to Acrivon Therapeutics and its Chief Legal Officer, Mary Miller. It does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• Shareholders: The direct beneficial ownership of the Chief Legal Officer decreased by 558 shares, a minor change resulting from a standard compensation event.

Key Dates

Recommendation

This Form 4 reports a routine disposition of shares for tax withholding upon RSU vesting by a Chief Legal Officer. It does not provide new information that would alter the fundamental investment thesis for Acrivon Therapeutics, hence a 'hold' recommendation is maintained.

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Mary Miller, Chief Legal Officer, Stock Disposition, Tax Withholding, Restricted Stock Units